This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | MicrobiomeTrials
← Back to trials NCT03258593
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Completed PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2018-06-07Est. Completion: 2022-08-01
Enrollment target: 15 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Bladder Cancer
This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-y…
Hong Kong, Hong Kong Est. completion Dec 31, 2029
Ganglioneuroblastoma, Nodular Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care su…
Birmingham, United States Est. completion Dec 31, 2029
Phase 2
Recruiting
Low-grade NMIBC FGFR Gene Amplification FGFR Gene Alterations FGFR3 Gene Alteration FGFR3 Gene Mutation FGFR3 Gene Fusions
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Homewood, United States Est. completion Feb 2028